All the news Showing 10 of 15 articles from: Experimental treatments for NASH/NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Advanced fibrosis in people with NAFLD increases the risk of liver complications Keith Alcorn / 08 December 2021 Advanced liver fibrosis in people with non-alcoholic fatty liver disease was associated with an increased risk of liver-related complications, a prospective study in the United States has found. Fat accumulation in the liver, ... Resmetirom reduces liver fat and fibrosis in people with NASH Liz Highleyman / 01 July 2021 Resmetirom, a thyroid hormone receptor agonist, appeared to reduce liver fat and fibrosis, as determined by biomarkers and non-invasive imaging, in people with non-alcoholic steatohepatitis (NASH), according to a presentation at the 2021 International ... Semaglutide alone or in combination regimens shows promise for NASH Liz Highleyman / 18 December 2020 Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, researchers reported at the AASLD virtual Liver Meeting. What's more, ... Lanifibranor improves NASH in 24-week trial Keith Alcorn / 18 December 2020 Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b clinical trial, Professor Sven Francque of Antwerp ... Efruxifermin improves liver fat and fibrosis in people with NASH Keith Alcorn / 15 December 2020 Efruxifermin reduced liver fat and improved liver inflammation and fibrosis in the majority of people with NASH who received it in a phase 2a trial but nausea and vomiting led 10% of ... Cotadutide improves metabolic and liver biomarkers in people with NAFLD and diabetes Liz Highleyman / 26 October 2020 Cotadutide, an experimental therapy that alters glucose and lipid metabolism, led to weight loss and improvements in metabolic, cardiovascular and liver fibrosis biomarkers in overweight people with diabetes and fatty liver disease, but ... Experimental NASH treatments: Gilead candidates miss primary endpoint but show some benefits Liz Highleyman / 20 October 2020 Combinations of experimental drugs for non-alcoholic steatohepatitis (NASH) failed to meet a study's primary endpoint by significantly improving liver fibrosis without worsening NASH, but one combination in particular – firsocostat plus ... Aldafermin reduces liver fat in phase 2 study Keith Alcorn / 14 September 2020 Aldafermin significantly reduced liver fat content and liver damage in a phase 2 study of a 24-week treatment course, Dr Stephen Harrison, Visiting Professor of Hepatology at the University of Oxford, told ... Two novel treatments show promise in improving biomarkers of NASH pathology EASL / 28 August 2020 HIV-positive people with fatty liver disease are at high risk for fibrosis Liz Highleyman / 23 March 2020 People living with HIV who have non-alcoholic fatty liver disease (NAFLD) often have liver fibrosis and are at risk for fibrosis worsening, researchers reported earlier this month at the Conference ... ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive